Literature DB >> 29528447

Clinical Use of Cerebrovascular Compliance Imaging to Evaluate Revascularization in Patients With Moyamoya.

Jennifer M Watchmaker1, Blaise deB Frederick2,3, Matthew R Fusco4, Larry T Davis5, Meher R Juttukonda1, Sarah K Lants1, Howard S Kirshner6, Manus J Donahue1,6,7.   

Abstract

BACKGROUND: Surgical revascularization is often performed in patients with moyamoya, however routine tools for efficacy evaluation are underdeveloped. The gold standard is digital subtraction angiography (DSA); however, DSA requires ionizing radiation and procedural risk, and therefore is suboptimal for routine surveillance of parenchymal health.
OBJECTIVE: To determine whether parenchymal vascular compliance measures, obtained noninvasively using magnetic resonance imaging (MRI), provide surrogates to revascularization success by comparing measures with DSA before and after surgical revascularization.
METHODS: Twenty surgical hemispheres with DSA and MRI performed before and after revascularization were evaluated. Cerebrovascular reactivity (CVR)-weighted images were acquired using hypercapnic 3-Tesla gradient echo blood oxygenation level-dependent MRI. Standard and novel analysis algorithms were applied (i) to quantify relative CVR (rCVRRAW), and decompose this response into (ii) relative maximum CVR (rCVRMAX) and (iii) a surrogate measure of the time for parenchyma to respond maximally to the stimulus, CVRDELAY. Measures between time points in patients with good and poor surgical outcomes based on DSA-visualized neoangiogenesis were contrasted (signed-rank test; significance: 2-sided P < .050).
RESULTS: rCVRRAW increases (P = .010) and CVRDELAY decreases (P = .001) were observed pre- vs post-revascularization in hemispheres with DSA-confirmed collateral formation; no difference was found pre- vs post-revascularization in hemispheres with poor revascularization. No significant change in rCVRMAX post-revascularization was observed in either group, or between any of the MRI measures, in the nonsurgical hemisphere.
CONCLUSION: Improvement in parenchymal compliance measures post-revascularization, primarily attributed to reductions in microvascular response time, is concurrent with collateral formation visualized on DSA, and may be useful for longitudinal monitoring of surgical outcomes.

Entities:  

Mesh:

Year:  2019        PMID: 29528447      PMCID: PMC6500903          DOI: 10.1093/neuros/nyx635

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  39 in total

1.  The Contribution of Common Surgically Implanted Hardware to Functional MR Imaging Artifacts.

Authors:  A A Desai; M K Strother; C C Faraco; V L Morgan; T R Ladner; L M Dethrage; L C Jordan; M J Donahue
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-13       Impact factor: 3.825

2.  Clinical features, surgical treatment, and long-term outcome in pediatric patients with moyamoya disease in China.

Authors:  Xiang-Yang Bao; Lian Duan; Wei-Zhong Yang; De-Sheng Li; Wei-Jian Sun; Zheng-Shan Zhang; Rui Zong; Cong Han
Journal:  Cerebrovasc Dis       Date:  2015-01-06       Impact factor: 2.762

3.  Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke.

Authors:  J H Pexman; P A Barber; M D Hill; R J Sevick; A M Demchuk; M E Hudon; W Y Hu; A M Buchan
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

4.  A theoretical framework for estimating cerebral oxygen metabolism changes using the calibrated-BOLD method: modeling the effects of blood volume distribution, hematocrit, oxygen extraction fraction, and tissue signal properties on the BOLD signal.

Authors:  Valerie E M Griffeth; Richard B Buxton
Journal:  Neuroimage       Date:  2011-06-06       Impact factor: 6.556

5.  Sequence-specific MR imaging findings that are useful in dating ischemic stroke.

Authors:  Laura M Allen; Anton N Hasso; Jason Handwerker; Hamed Farid
Journal:  Radiographics       Date:  2012 Sep-Oct       Impact factor: 5.333

6.  Monitoring Cerebrovascular Reactivity through the Use of Arterial Spin Labeling in Patients with Moyamoya Disease.

Authors:  Tae Jin Yun; Jin Chul Paeng; Chul-Ho Sohn; Jeong Eun Kim; Hyun-Seung Kang; Byung-Woo Yoon; Seung Hong Choi; Ji-hoon Kim; Ho-Young Lee; Moon Hee Han; Greg Zaharchuk
Journal:  Radiology       Date:  2015-07-21       Impact factor: 11.105

Review 7.  Moyamoya disease and moyamoya syndrome.

Authors:  R Michael Scott; Edward R Smith
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

8.  Indirect Bypass Surgery May Be More Beneficial for Symptomatic Patients with Moyamoya Disease at Early Suzuki Stage.

Authors:  Lin Wang; Cong Qian; Xiaobo Yu; Xiongjie Fu; Ting Chen; Chi Gu; Jingyin Chen; Gao Chen
Journal:  World Neurosurg       Date:  2016-08-02       Impact factor: 2.104

9.  CO2 blood oxygen level-dependent MR mapping of cerebrovascular reserve in a clinical population: safety, tolerability, and technical feasibility.

Authors:  Vincent R Spano; Daniel M Mandell; Julien Poublanc; Kevin Sam; Anne Battisti-Charbonney; Olivia Pucci; Jay S Han; Adrian P Crawley; Joseph A Fisher; David J Mikulis
Journal:  Radiology       Date:  2012-11-30       Impact factor: 11.105

10.  Stroke prevention by direct revascularization for patients with adult-onset moyamoya disease presenting with ischemia.

Authors:  Tackeun Kim; Chang Wan Oh; O-Ki Kwon; Gyojun Hwang; Jeong Eun Kim; Hyun-Seung Kang; Won-Sang Cho; Jae Seung Bang
Journal:  J Neurosurg       Date:  2015-12-04       Impact factor: 5.115

View more
  8 in total

1.  Editorial for "Pre-Surgical Magnetic Resonance Imaging Indicators of Revascularization Response in Adults With Moyamoya Vasculopathy".

Authors:  Yibin Xie
Journal:  J Magn Reson Imaging       Date:  2022-03-17       Impact factor: 5.119

2.  Choroid plexus perfusion and intracranial cerebrospinal fluid changes after angiogenesis.

Authors:  Skylar E Johnson; Colin D McKnight; Sarah K Lants; Meher R Juttukonda; Matthew Fusco; Rohan Chitale; Paula C Donahue; Daniel O Claassen; Manus J Donahue
Journal:  J Cereb Blood Flow Metab       Date:  2019-09-09       Impact factor: 6.200

3.  Classifying intracranial stenosis disease severity from functional MRI data using machine learning.

Authors:  Spencer L Waddle; Meher R Juttukonda; Sarah K Lants; Larry T Davis; Rohan Chitale; Matthew R Fusco; Lori C Jordan; Manus J Donahue
Journal:  J Cereb Blood Flow Metab       Date:  2019-05-08       Impact factor: 6.200

4.  A Prospective, Longitudinal Magnetic Resonance Imaging Evaluation of Cerebrovascular Reactivity and Infarct Development in Patients With Intracranial Stenosis.

Authors:  Meher R Juttukonda; Larry T Davis; Sarah K Lants; Spencer L Waddle; Chelsea A Lee; Niral J Patel; Lori C Jordan; Manus J Donahue
Journal:  J Magn Reson Imaging       Date:  2021-03-24       Impact factor: 5.119

5.  Hypercapnic BOLD MRI compared to H215O PET/CT for the hemodynamic evaluation of patients with Moyamoya Disease.

Authors:  Till-Karsten Hauser; Achim Seeger; Benjamin Bender; Uwe Klose; Johannes Thurow; Ulrike Ernemann; Marcos Tatagiba; Philipp T Meyer; Nadia Khan; Constantin Roder
Journal:  Neuroimage Clin       Date:  2019-02-04       Impact factor: 4.881

6.  Cerebrovascular Reactivity Measurement Using Magnetic Resonance Imaging: A Systematic Review.

Authors:  Emilie Sleight; Michael S Stringer; Ian Marshall; Joanna M Wardlaw; Michael J Thrippleton
Journal:  Front Physiol       Date:  2021-02-25       Impact factor: 4.566

7.  Hemodynamic impairments within individual watershed areas in asymptomatic carotid artery stenosis by multimodal MRI.

Authors:  Stephan Kaczmarz; Jens Göttler; Jan Petr; Mikkel Bo Hansen; Kim Mouridsen; Claus Zimmer; Fahmeed Hyder; Christine Preibisch
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-01       Impact factor: 6.200

Review 8.  Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Weiping Xiao; Qing Zhang; Ding Xia; Peng Gao; Jiabin Su; Heng Yang; Xinjie Gao; Wei Ni; Yu Lei; Yuxiang Gu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.